Animal Or Plant Cell Patents (Class 424/93.7)
-
Patent number: 11542328Abstract: The present invention relates in part to the discovery of genes that are deregulated in cancer stem cells (e.g., melanoma stem cells). In some aspects, methods for treating individuals having melanoma are provided; the methods involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes. In other aspects, cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. Other aspects of the invention relate to reagents, arrays, compositions, and kits that are useful for diagnosing and treating melanoma.Type: GrantFiled: June 10, 2019Date of Patent: January 3, 2023Assignees: The Brigham and Women's Hospital, Inc., Children's Medical Center CorporationInventors: Markus H. Frank, Natasha Y. Frank
-
Patent number: 11534401Abstract: A room temperature injectable thermo-responsive hydrogel comprises a P407 poloxamer base hydrogel, chitosan, 2-Hydroxypropyl ?-cyclodextrin and genipin. The chitosan and genipin form an interpenetrating scaffold within the hydrogel in which the chitosan is crosslinked with genipin. Chemotherapeutic drugs can be added to the hydrogel singly or in combination in effective amounts without any loss of thermo-responsiveness in the hydrogel. Therapeutic use of the thermo-responsive hydrogel in the intratumoural treatment of solid cancer is also described.Type: GrantFiled: November 7, 2018Date of Patent: December 27, 2022Assignee: THE ROYAL COLLEGE OF SURGEONS IN IRELANDInventors: Helena Kelly, Garry Duffy, Seona Rossi, Conn Hastings
-
Patent number: 11530384Abstract: The invention relates to the use of matrix cells for obtaining a micro hair follicle and to the use thereof for evaluating the effect of cosmetic, pharmaceutical or dermatological products and also for the prophylactic or therapeutic treatment of a state of reduced pilosity.Type: GrantFiled: September 28, 2016Date of Patent: December 20, 2022Assignee: L'OREALInventors: Khalid Bakkar, Christine Collin-Djangone
-
Patent number: 11529300Abstract: Provided are formulations that interact with the skin microbiome of a human patient such that when applied topically in therapeutically effective amounts at prescribed intervals, the formulations cause an increase in skin firmness, density, smoothness, elasticity and thickness resulting in a skin appearance that reflects overall skin health. In exemplary embodiments formulations include, without limitation, the following active components acting in concert with each other: a prebiotic component, a peptide component, a matrix metalloproteinases (MMPs) inhibitor component; and an antioxidant component; all present in a carrier base. The exemplary embodiments may be in the form of a cream, a lotion, a serum, or a hydrogel that facilitates delivery of these active components into the skin.Type: GrantFiled: July 3, 2019Date of Patent: December 20, 2022Assignee: JAMRM, LLCInventors: Tatiana Kelly, Alisar Salah Zahr, John Koch, Nirmal Shah, Thu Quynh Nguyen
-
Patent number: 11512283Abstract: Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of maintaining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.Type: GrantFiled: June 27, 2019Date of Patent: November 29, 2022Assignee: Technion Research & Development Foundation LimitedInventors: Michal Amit, Joseph Itskovitz-Eldor
-
Patent number: 11510946Abstract: Methods of treating progressive forms of multiple sclerosis are provided, comprising administering adipose-derived stem cells into the central nervous system (CNS). Further provided are improved methods for obtaining ADSCs, which are more cost effective and which provide higher yields compared to currently used methods.Type: GrantFiled: May 14, 2018Date of Patent: November 29, 2022Assignee: STEM CELL MEDICINE LTD.Inventors: Ehud Marom, Frida Grynspan, Dima Yudin
-
Patent number: 11512282Abstract: Provided herein are placental stem cells that exhibit increased survival (“enhanced placental stem cells”), compositions comprising such placental stem cells, and methods of using such placental stem cells and compositions.Type: GrantFiled: April 15, 2019Date of Patent: November 29, 2022Assignee: Celularity Inc.Inventors: Stewart Abbot, Katarzyna Karasiewicz-Mendez, Robert J Hariri, Xiaokui Zhang
-
Patent number: 11512291Abstract: Disclosed herein are methods for generating satellite cells and compositions including satellite cells.Type: GrantFiled: March 8, 2019Date of Patent: November 29, 2022Assignee: President and Fellows of Harvard CollegeInventors: Lee L. Rubin, Feodor D. Price
-
Patent number: 11504399Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoietic cells are obtained by separating the T cells from the immature hematopoietic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject.Type: GrantFiled: August 13, 2019Date of Patent: November 22, 2022Assignee: Yeda Research and Development Co. Ltd.Inventors: Yair Reisner, Esther Bachar-Lustig
-
Patent number: 11497776Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.Type: GrantFiled: July 11, 2019Date of Patent: November 15, 2022Assignee: Yeda Research and Development Co. Ltd.Inventors: Yair Reisner, Esther Bachar-Lustig
-
Patent number: 11491188Abstract: The present disclosure relates to methods for preventing progressive heart failure in subjects with persistent left ventricular (LV) dysfunction. Such methods may also be used for treating or preventing progressive heart failure in subjects with a proximal left anterior descending (LAD) lesion and persistent left ventricular dysfunction.Type: GrantFiled: December 22, 2015Date of Patent: November 8, 2022Assignee: MESOBLAST INTERNATIONAL SARLInventors: Silviu Itescu, Lee Golden
-
Patent number: 11492599Abstract: The present invention relates to methods for generating Induced Pluripotent Stem Cells from fibroblast cells. The invention also relates to appropriate culture media used by the method disclosed; pluripotent stem cells, cultures of the pluripotent stem cells, differentiated cells derived from the culture pluripotent stem cells isolated by the methods disclosed and uses for those cells, e.g. therapeutic uses, such as autologous cell therapy procedures.Type: GrantFiled: April 18, 2017Date of Patent: November 8, 2022Assignee: KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTREInventors: Abdelilah Aboussekhra, Hazem Ghebeh, Fauziah Hendrayani
-
Patent number: 11471398Abstract: The present invention provides devices and methods for delivering a population of cells or a therapeutic agent to a subject in need thereof.Type: GrantFiled: March 6, 2019Date of Patent: October 18, 2022Assignee: Vertex Pharmaceuticals IncorporatedInventors: Christopher Thanos, Yang Qui
-
Patent number: 11471517Abstract: ILC2 cells play a role in the pathogenesis of graft versus host disease (GvHD) and idiopathic pneumonia syndrome (IPS), both conditions associated with allogeneic stem cell transplantation. Infusion of IL-33 activated ILC2 cells into patients with ongoing GvHD or IPS, or prior to onset of GvHD or IPS in susceptible patients, substantially ameliorates the disease and improves survival.Type: GrantFiled: October 10, 2019Date of Patent: October 18, 2022Assignees: The University of North Carolina at Chapel Hill, Regents of the University of MinnesotaInventors: Jonathan Serody, James Coghill, Danny Bruce, Bruce Blazar, Heather Stefanski, Benjamin Vincent
-
Patent number: 11466254Abstract: Provided herein are a method of promoting osteogenic differentiation efficiency of a stem cell or of inducing chondrogenic differentiation of a stem cell, comprising treating the stem cell with a culture solution of chicken bone marrow-derived osteochondroprogenitor cells; a method of preventing or treating cartilage damage or a cartilage defect disease comprising administering to a subject in need thereof a composition comprising a differentiation-induced stem cell or differentiated chondrocyte made by said method as an active ingredient; and a method of preventing or treating a bone disease, cartilage damage, or a cartilage defect disease comprising administering to a subject in need thereof, a composition comprising a culture solution or culture concentrate of chicken bone marrow-derived osteochondroprogenitor cells as an active ingredient.Type: GrantFiled: October 16, 2018Date of Patent: October 11, 2022Assignee: SEOUL NATIONAL UNIVERSITY R & DB FOUNDATIONInventors: Jeong Mook Lim, Ji Yeon Ahn
-
Patent number: 11452797Abstract: The invention provides a method to prepare a graft comprising a recellularized extracellular matrix of a mammalian liver, liver lobe or portion thereof, and a method of using the recellularized extracellular matrix of a mammalian liver, liver lobe or portion thereof.Type: GrantFiled: January 9, 2019Date of Patent: September 27, 2022Assignee: Miromatrix Medical Inc.Inventor: Jeffrey Ross
-
Patent number: 11453005Abstract: Various embodiments comprise systems, methods, architectures, mechanisms or apparatus configured to separate particles of varying size within a fluid flow, or filter particles from a fluid flow, via an array of anchored-liquid drops or anchored-gas drops.Type: GrantFiled: May 25, 2018Date of Patent: September 27, 2022Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: German Drazer, Shahab Shojaei-Zadeh
-
Patent number: 11446308Abstract: In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: December 9, 2019Date of Patent: September 20, 2022Inventors: Jian Zuo, Tai Teitz, Jie Fang, Asli Goktug, Taosheng Chen, Jaeki Min, R. Kiplin Guy
-
Patent number: 11447750Abstract: Methods are provided for extracting bone marrow cells from bone obtained from deceased donors, for preparing the bone marrow for cryopreservation and for obtaining desired cells from cryopreserved and fresh bone marrow.Type: GrantFiled: September 4, 2020Date of Patent: September 20, 2022Assignee: Ossium Health, Inc.Inventors: Erik John Woods, Brian H. Johnstone, Dongsheng Gu, Aubrey Marie Sherry, Kelsey Gwen Musall, John R. Woods, James Hardin, Alan Hooks
-
Patent number: 11446335Abstract: A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.Type: GrantFiled: June 25, 2019Date of Patent: September 20, 2022Assignee: ViaCyte, Inc.Inventors: Alan D. Agulnick, Kevin Allen D'Amour
-
Patent number: 11439960Abstract: An object of the present invention is to provide a cell transplant device having an ability to induce angiogenesis around the cell transplant device, and a method for manufacturing the same. According to the present invention, a cell transplant device including a cell structure (A) that includes a plurality of biocompatible polymer blocks and a plurality of cells of at least one type, and in which at least one of the biocompatible polymer blocks is disposed in gaps between the plurality of cells; and an immunoisolation membrane (B) that encloses the cell structure is provided.Type: GrantFiled: February 28, 2020Date of Patent: September 13, 2022Assignee: FUJIFILM CorporationInventors: Kentaro Nakamura, Ryo Kogawa, Yusuke Mochizuki, Ryuta Takegami
-
Patent number: 11439667Abstract: The present invention relates to methods, kits and compositions for expansion of embryonic hematopoietic stem cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TGF? pathway. Also provided herein are methods for expanding embryonic hematopoietic stem cells using kits and compositions comprising a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TGF? pathway. The embryonic hematopoietic stem cells expanded using the disclosed kits, compositions and methods include cells derived from an embryo (e.g., aorta-gonad-mesonephros region of the embryo), embryonic stem cells, induced pluripotent stem cells, or reprogrammed cells of other types.Type: GrantFiled: October 17, 2019Date of Patent: September 13, 2022Assignee: FRED HUTCHINSON CANCER CENTERInventors: Irwin D. Bernstein, Brandon K. Hadland
-
Patent number: 11440927Abstract: A hydroxyapatite particle having a plurality of functionalities on a surface, a process for forming a hydroxyapatite particle having a plurality of functionalities on a surface, and an article of manufacture including a hydroxyapatite particle having a plurality of functionalities on a surface are disclosed. The hydroxyapatite particle includes a first functionality on a first surface of the hydroxyapatite particle, where the first functionality includes first moieties to bind to polymer constructs, and a second functionality on a second surface of the hydroxyapatite particle. The process for forming the hydroxyapatite particle includes providing one or more hydroxyapatite particles, forming one or more wax particles, functionalizing a first exposed surface of the one or more hydroxyapatite particles, removing the one or more hydroxyapatite particles from the wax core, and functionalizing the second exposed surface of the one or more hydroxyapatite particles.Type: GrantFiled: November 28, 2017Date of Patent: September 13, 2022Assignee: International Business Machines CorporationInventors: Sarah Czaplewski-Campbell, Jason T. Wertz, Brandon M. Kobilka, Eric Campbell
-
Patent number: 11426431Abstract: This document provides methods and materials for treating multiple system atrophy in a mammal. Specifically, the methods comprises intrathecally administering to the mammal a composition comprising autologous mesenchymal stem cells (e.g. adipose deprived mesenchymal stem cells) to treat multiple system atrophy. Further disclosed is the composition comprising from about 5×10(6) to about 5×10(8) autologous mesenchymal stem cells.Type: GrantFiled: June 15, 2016Date of Patent: August 30, 2022Assignee: Mayo Foundation for Medical Education and ResearchInventors: Wolfgang Singer, Phillip Low
-
Patent number: 11427807Abstract: The present disclosure relates to a serum-free medium for culturing of DS cells containing platelet derived growth factor (PDGF), or to a method for culturing of dermal sheath (DS) cells, using serum-free medium comprising PDGF.Type: GrantFiled: July 7, 2017Date of Patent: August 30, 2022Assignee: Shiseido Company, Ltd.Inventors: Haruyo Yamanishi, Tsutomu Soma, Yuzo Yoshida
-
Patent number: 11426425Abstract: The present invention has an objective of providing a novel composition for treating a fibrocartilaginous tissue injury. The present invention provides a composition for treating a fibrocartilaginous tissue injury, which is to be applied to an injured fibrocartilaginous tissue part of a target and which comprises a monovalent metal salt of alginic acid, more preferably a low endotoxin monovalent metal salt of alginic acid.Type: GrantFiled: March 1, 2018Date of Patent: August 30, 2022Assignees: Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido UniversityInventors: Eiji Kondo, Norimasa Iwasaki, Tomohiro Onodera, Wooyoung Kim, Yasuyuki Kawaguchi
-
Patent number: 11426433Abstract: A therapeutic composition can include an amount of amniotic fluid having a therapeutically effective amount of at least one protein, hyaluronic acid, or both. The therapeutic composition can be substantially free of lanugo, vernix, and cells harvested with the amniotic fluid.Type: GrantFiled: February 11, 2020Date of Patent: August 30, 2022Assignee: University of Utah Research FoundationInventors: Jo-Anna Reems, Jan Pierce
-
Patent number: 11426494Abstract: A method for preparing a laminate coronary stent comprising: providing a stent framework; and depositing a plurality of layers on said stent framework to form said laminate coronary stent; wherein at least one of said layers comprises a bioabsorbable polymer.Type: GrantFiled: February 7, 2020Date of Patent: August 30, 2022Assignee: MT Acquisition Holdings LLCInventors: James B. McClain, Charles Douglas Taylor, Robert Rabiner
-
Porous affinity hydrogel particles for reducing the bioavailability of selected biological molecules
Patent number: 11414483Abstract: A hydrogel particle that has an average cross-sectional diameter in the range from 1 micrometer (?m) to 1000 ?m, wherein the particle includes a first polymer network with an average mesh size that allows diffusion of a molecule with an hydrodynamic radius of 1000 nanometer (nm) or less into the first polymer network and which particle includes one or more binding molecules that are immobilized by the polymer network. The hydrogel particle preferably has wherein the first polymer network has an average mesh size that prevents diffusion of a molecule with an average hydrodynamic radius of more than 1000 nm to diffuse into the first polymer network, preferably the mesh size prevents diffusion of a molecule with an average hydrodynamic radius of more than 100 nm, and preferably more than 5 nm. Methods for reducing the bioavailability of one or more soluble biological molecules in a biological system by using the described hydrogel particle.Type: GrantFiled: January 18, 2019Date of Patent: August 16, 2022Assignee: HY2CARE B.V.Inventors: Tom Kamperman, Lisanne Paula Karbaat, Hermanus Bernadus Johannes Karperien, Jeroen Christianus Hermanus Leijten, Pieter Jelle Dijkstra, Bram Zoetebier -
Patent number: 11413311Abstract: Methods of treating multiple sclerosis are provided, comprising parenterally administering glatiramer acetate in a sustained-release depot form, and administering adipose-derived stem cells into the central nervous system. According to some aspects the combined treatments provide synergistic effects. In particular the combined therapies offer benefits to progressive forms of multiple sclerosis.Type: GrantFiled: May 15, 2017Date of Patent: August 16, 2022Assignees: MAPI PHARMA LTD., STEM CELL MEDICINE LTD.Inventors: Ehud Marom, Nadav Bleich Kimelman, Frida Grynspan
-
Patent number: 11413286Abstract: Disclosed herein are methods of reprograming autologous tissues or cells into astrocytes or astroglial progenitor cells using one or more small molecule compounds only without any transgenes. Also disclosed are methods of preventing or treating neurodegenerative diseases or neurological disorders associated with dysfunction of astrocytes, such as Alzheimer's Disease, by transplanting the astrocytes or astroglial progenitor cells produced by the methods disclosed herein into the brain of a subject suffering from the neurodegenerative disease or neurological disorder.Type: GrantFiled: June 21, 2017Date of Patent: August 16, 2022Assignee: CITY OF HOPEInventors: Yanhong Shi, E. Tian
-
Patent number: 11406668Abstract: The present invention provides a pharmaceutical composition for use in modifying scalp or skin, promoting wound healing, or modifying hair, comprising a secretion from adipose stem cells as an active ingredient, wherein 0.3 to 0.6 ?g of the secretion in terms of protein abundance per site in scalp or skin is administered.Type: GrantFiled: October 2, 2017Date of Patent: August 9, 2022Inventor: Hirotaro Fukuoka
-
Patent number: 11406670Abstract: A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.Type: GrantFiled: February 21, 2019Date of Patent: August 9, 2022Assignee: Yeda Research and Development Co. Ltd.Inventors: Michel Revel, Judith Chebath, Michal Izrael, Rosalia Kaufman
-
Patent number: 11390851Abstract: The present invention provides a method for generation, isolation, detection and/or analysis of cardiomyocytes derived from a starting cell composition comprising pluripotent and/or multipotent stem cells, the method comprising the steps a) differentiating said pluripotent and/or multipotent stem cells into cardiovascular cells, thereby generating a sample comprising cardiomyocytes and non-cardiomyocytes; and b) labeling the non-cardiomyocytes of said sample with more than one antibody or antigen binding fragment thereof specific for antigens of non-cardiomyocytes and c) depleting said labeled non-cardiomyocytes from said sample; and optionally d) labeling the cardiomyocytes of said sample with at least one antibody or antigen binding fragment thereof specific for antigen(s) of cardiomyocytes; and e) enriching said labeled cardiomyocytes and detecting and isolating cardiomyocyte subtypes derived from said pluripotent and/or multipotent stem cells.Type: GrantFiled: May 30, 2017Date of Patent: July 19, 2022Assignee: Miltenyi Biotec B.V. & Co. KGInventors: Kristin Becker, Dominik Eckardt, Andreas Bosio
-
Patent number: 11389616Abstract: A method of preparing adipose tissue for transplantation, from lobular fat extracted, for instance, by liposuction, the fat including a fluid component that also includes an oily component, a blood component and/or sterile solutions and of a solid component that includes cell fragments, cells and one or more cell macroagglomerates of heterogeneous size, characterized in that it includes at least one step of forming an emulsion of the fluid component in the sterile washing solution by active and/or passive stirring and discharging the emulsion from the outlet through a density gradient.Type: GrantFiled: April 11, 2019Date of Patent: July 19, 2022Assignee: LIPOGEMS INTERNATIONAL S.P.A.Inventor: Carlo Tremolada
-
Patent number: 11376348Abstract: Disclosed are products and methods for treating soft tissue injuries. The provided methods include the production of processed or cryopreserved microvascular tissue. Also provided are products and methods of using processed or cryopreserved microvascular tissue for the treatment of soft tissue injuries.Type: GrantFiled: October 5, 2018Date of Patent: July 5, 2022Assignee: Micro Vascular Tissues, Inc.Inventors: Dale R. Peterson, Richard B. Emmitt
-
Patent number: 11345889Abstract: The present invention provides an artificial tissue culture comprising a heterogeneous population of cells of at least two different tissue sections, wherein said tissue sections are in a three dimensional structure, method of generating such a tissue and kits suitable for said method or maintain a three dimensional tissue culture.Type: GrantFiled: July 23, 2019Date of Patent: May 31, 2022Assignee: IMBA-Institut fur Molekulare Biotechnologie GMBHInventors: Juergen Knoblich, Madeline A. Lancaster
-
Patent number: 11344577Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf” treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.Type: GrantFiled: July 8, 2019Date of Patent: May 31, 2022Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Laurence J. Neil Cooper, Hiroki Torikai
-
Patent number: 11338292Abstract: A microfluidic particle sorting apparatus for capturing targets from fluid containing the targets is disclosed. The apparatus includes an inlet for receiving the fluid; a sorting chamber allowing the fluid to flow through; a first outlet for discharging the fluid after flowing through the sorting chamber; a capturing structure for capturing the cells, wherein the capturing structure is upstream of the first outlet, and includes obstacles in an array, each extending through the sorting chamber in a lateral direction with respect to a fluid flow of the fluid; and a second outlet upstream of the capturing structure comprising a plurality of openings; wherein a gap between two adjacent obstacles is equal to or greater than each opening of the second outlet.Type: GrantFiled: March 12, 2019Date of Patent: May 24, 2022Assignee: BOE Technology Group Co., Ltd.Inventors: Zhihong Wu, Defeng Mao, Zijian Zhao, Yudan Yin
-
Patent number: 11332715Abstract: Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability. In addition, the mesenchymal stem cells prepared by the culturing method are effectively used to treat or improve a pulmonary disease.Type: GrantFiled: March 29, 2019Date of Patent: May 17, 2022Assignee: MEDIPOST CO., LTDInventors: Yoon-Sun Yang, Won Il Oh, Sun Jae Kwon, Mi Yeon Lee, Hong Bae Jeon
-
Patent number: 11324215Abstract: A viable disc regenerative composition has a micronized material of nucleus pulposus and a biological composition made from a mixture of mechanically selected allogeneic biologic material derived from bone marrow having non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components; and wherein the mixture is compatible with biologic function and further includes non-expanded whole cells. The biological composition is predisposed to demonstrate or support elaboration of active volume or spatial geometry consistent in morphology with that of disc tissue. The viable disc regenerative composition extends regenerative resonance that compliments or mimics disc tissue complexity.Type: GrantFiled: February 6, 2019Date of Patent: May 10, 2022Assignee: Vivex Biologies Group, Inc.Inventors: Harry Thomas Temple, Timothy Ganey, Stephanie Gonzalez, Tracy Scott Anderson, Shabnam Namin
-
Patent number: 11324858Abstract: The present disclosure provides patterned biomaterials having organized cords and extracellular matrix embedded in a 3D scaffold. According, the present disclosure provides compositions and applications for patterned biomaterials. Pre-patterning of these biomaterials can lead to enhanced integration of these materials into host organisms, providing a strategy for enhancing the viability of engineered tissues by promoting vascularization.Type: GrantFiled: March 26, 2021Date of Patent: May 10, 2022Assignees: The Trustees of the University of Pennsylvania, Massachusetts Institute of TechnologyInventors: Christopher S. Chen, Jan D. Baranski, Ritika Chaturvedi, Michael T. Yang, Kelly R. Stevens, Sangeeta N. Bhatia
-
Patent number: 11318170Abstract: The invention relates to the treatment of chronic stroke, traumatic brain injury, and neurodegenerative disorders using umbilical cord blood cells.Type: GrantFiled: March 26, 2009Date of Patent: May 3, 2022Assignee: StemCyte, Inc.Inventors: Shinn-Zong Lin, Woei-Cherng Shyu, Hung Li
-
Patent number: 11278574Abstract: The invention provides pharmaceutical compositions comprising human immature dental pulp stem cells (hIDPSCs) wherein the hIDPSCs express CD44 and CD13. The invention also provides methods of treating a neurological disease or condition comprising systemically administering to a subject a pharmaceutical composition comprising hIDPSCs wherein the hIDPSCs express CD44 and CD13. For example, for treating neurological diseases or conditions including supporting the neuro-protective mechanism in subjects diagnosed with early HD or repairing lost DA neurons in subjects diagnosed with PD.Type: GrantFiled: September 8, 2018Date of Patent: March 22, 2022Assignees: AVITA INTERNATIONAL LTD., FUNDAÇÂO BUTANTANInventors: Irina Kerkis, Cristiane Valverde Wenceslau
-
Patent number: 11278710Abstract: Methods and devices related to the fields of skin care, hair restoration and lip care wherein the systems may be used by an individual for infusing treatment media into skin or lips for cosmetic and rejuvenation purposes, hair restoration purposes or other therapeutic purposes.Type: GrantFiled: August 25, 2021Date of Patent: March 22, 2022Assignee: Hermes Innovations, LLCInventor: John H. Shadduck
-
Patent number: 11278042Abstract: A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR2) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.Type: GrantFiled: December 28, 2020Date of Patent: March 22, 2022Assignee: IMMUNOLIGHT, LLCInventors: Frederic A. Bourke, Jr., Zakaryae Fathi, Harold Walder, Wayne F. Beyer, Jr.
-
Patent number: 11274280Abstract: The present invention relates to generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors. The present invention also relates to functional beta cells produced by said methods and uses of said beta cells.Type: GrantFiled: February 24, 2017Date of Patent: March 15, 2022Assignee: Novo Nordisk A/SInventors: Nicolaj Stroeyer Christophersen, Ulrik Doehn, Mattias Hansson
-
Patent number: 11273193Abstract: The invention relates to a synergistic composition comprising a dry extract of plant of genus Galeopsis and a compound promoting autophagy selected from biotin and R-N1-spermidine or a salt thereof, wherein R is hydrogen or methyl and mixtures thereof. The synergistic compositions according to the invention may be in the form of a topical formulation or oral formulation and is useful as a promoter of autophagy especially in cells of human scalp hair follicles and in promoting hair growth and/or in the treatment of hair thinning or hair loss.Type: GrantFiled: August 2, 2018Date of Patent: March 15, 2022Assignee: GIULIANI S.P.A.Inventors: Giammaria Giuliani, Ralf Paus, Benedetto Grimaldi, Barbara Marzani, Sergio Baroni
-
Patent number: 11273179Abstract: The invention provides methods of treating non-cancerous disorders in a subject by providing the subject with compositions containing hematopoietic cells. In certain embodiments, the compositions include CD34+ cells and CD3+ cells. In certain embodiments, the compositions include CD34+ cells and facilitating cells. The methods are useful for treating blood cell disorders and other disorders that can be ameliorated by providing donor hematopoietic cells.Type: GrantFiled: March 12, 2019Date of Patent: March 15, 2022Assignee: MEDEOR THERAPEUTICS, INC.Inventors: Steven R. Deitcher, Corinna X. Chen
-
Patent number: 11274276Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.Type: GrantFiled: January 17, 2020Date of Patent: March 15, 2022Assignee: Histogen, Inc.Inventors: Gail K. Naughton, Francis C. Zeigler, Mark Baumgartner, Kyle Nickey